Literature DB >> 19181793

Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability.

Giovanna Meloni, Marco Mancini, Valentina Gianfelici, Maria Paola Martelli, Robin Foa, Brunangelo Falini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19181793      PMCID： PMC2635402          DOI： 10.3324/haematol.2008.000059

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia.

Authors:  Niccolò Bolli; Sara Galimberti; Maria P Martelli; Alessia Tabarrini; Giovanni Roti; Cristina Mecucci; Massimo F Martelli; Mario Petrini; Brunangelo Falini
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

2.  Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.

Authors:  Brunangelo Falini; Maria Paola Martelli; Niccolò Bolli; Rossella Bonasso; Emanuela Ghia; Maria Teresa Pallotta; Daniela Diverio; Ildo Nicoletti; Roberta Pacini; Alessia Tabarrini; Barbara Verducci Galletti; Roberta Mannucci; Giovanni Roti; Roberto Rosati; Giorgina Specchia; Arcangelo Liso; Enrico Tiacci; Myriam Alcalay; Lucilla Luzi; Sara Volorio; Loris Bernard; Anna Guarini; Sergio Amadori; Franco Mandelli; Fabrizio Pane; Francesco Lo-Coco; Giuseppe Saglio; Pier-Giuseppe Pelicci; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

3.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).

Authors:  Bruno C Medeiros; Mark D Minden; Andre C Schuh; Aaron D Schimmer; Karen Yee; Jeff H Lipton; Hans A Messner; Vikas Gupta; Kathy Chun; Wei Xu; Prabodh Das; Suzanne Kamel-Reid; Joseph M Brandwein
Journal:  Leuk Lymphoma       Date:  2007-01

Review 5.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

Authors:  Brunangelo Falini; Ildo Nicoletti; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

6.  NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia.

Authors:  Michela Palmisano; Tiziana Grafone; Emanuela Ottaviani; Nicoletta Testoni; Michele Baccarani; Giovanni Martinelli
Journal:  Haematologica       Date:  2007-09       Impact factor: 9.941

7.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

8.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution.

Authors:  Wen-Chien Chou; Jih-Luh Tang; Liang-In Lin; Ming Yao; Woei Tsay; Chien-Yuan Chen; Shang-Ju Wu; Chi-Fei Huang; Rong-Jing Chiou; Mei-Hsuan Tseng; Dong-Tsamn Lin; Kai-Hsin Lin; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

9.  A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).

Authors:  Arcangelo Liso; Filippo Castiglione; Antonio Cappuccio; Fabrizio Stracci; Richard F Schlenk; Sergio Amadori; Christian Thiede; Susanne Schnittger; Peter J M Valk; Konstanze Döhner; Massimo F Martelli; Markus Schaich; Jürgen Krauter; Arnold Ganser; Maria P Martelli; Niccolò Bolli; Bob Löwenberg; Torsten Haferlach; Gerhard Ehninger; Franco Mandelli; Hartmut Döhner; Franziska Michor; Brunangelo Falini
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

10.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205
View more
  9 in total

1.  Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia.

Authors:  Ulrike Bacher; Naomi Porret; Raphael Joncourt; Javier Sanz; Nijas Aliu; Gertrud Wiedemann; Barbara Jeker; Yara Banz; Thomas Pabst
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941

Review 2.  Is acute myeloid leukemia a liquid tumor?

Authors:  Maro Ohanian; Stefan Faderl; Farhad Ravandi; Naveen Pemmaraju; Guillermo Garcia-Manero; Jorge Cortes; Zeev Estrov
Journal:  Int J Cancer       Date:  2013-02-04       Impact factor: 7.396

3.  Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.

Authors:  Nuria Mencia-Trinchant; Yang Hu; Maria Antonina Alas; Fatima Ali; Bas J Wouters; Sangmin Lee; Ellen K Ritchie; Pinkal Desai; Monica L Guzman; Gail J Roboz; Duane C Hassane
Journal:  J Mol Diagn       Date:  2017-05-16       Impact factor: 5.568

Review 4.  Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Authors:  P Sportoletti; E Varasano; R Rossi; A Mupo; E Tiacci; G Vassiliou; M P Martelli; B Falini
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

5.  Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia.

Authors:  Jing Quan; Yu-jie Gao; Zai-lin Yang; Hui Chen; Jing-rong Xian; Shuai-shuai Zhang; Qin Zou; Ling Zhang
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

6.  Examination of the FLT3 and NPM1 mutational status in patients with acute myeloid leukemia from southeastern Poland.

Authors:  Dorota Koczkodaj; Szymon Zmorzyński; Małgorzata Michalak-Wojnowska; Ewa Wąsik-Szczepanek; Agata A Filip
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

Review 7.  Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.

Authors:  Fabio Forghieri; Patrizia Comoli; Roberto Marasca; Leonardo Potenza; Mario Luppi
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

8.  Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.

Authors:  Petra Kövy; Zoltán Őrfi; András Bors; András Kozma; László Gopcsa; János Dolgos; Nóra Lovas; József Harasztdombi; Viktor Lakatos; Ágnes Király; Gábor Mikala; István Vályi-Nagy; Péter Reményi; Hajnalka Andrikovics
Journal:  PLoS One       Date:  2021-06-21       Impact factor: 3.752

Review 9.  The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms.

Authors:  Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-01-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.